The role of [
FAPI
PET/CT
RCC
Renal cell carcinoma
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 Oct 2023
07 Oct 2023
Historique:
received:
07
08
2023
accepted:
27
09
2023
medline:
7
10
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
aheadofprint
Résumé
We aimed to investigate the role of [ Twenty patients with a suspicious lesion considered primary renal malignancy or a history of RCC were included in our study. Two patients were excluded from further analyses due to other confirmed malignancies. Six patients were newly diagnosed, while the indication of 12 patients was restaging. All patients underwent [ We detected 90 lesions in 18 patients with varying FAPI and FDG uptake values on both PET/CT. The median TBR of FAPI-PET/CT of all lesions was higher than TBR of FDG-PET/CT with statistically significance (5.6 vs. 2.1, p < 0.001). In primary and recurrent lesions, the median SUVmax, TBR, and tumor volume on FAPI-PET/CT were higher than FDG-PET/CT. The median SUVmax of lung lesions on FAPI-PET/CT was statistical significantly higher than FDG-SUVmax (3.8 vs. 1.8, p = 0.02). The median of FAPI-SUVmax on primary lesions was lower in the early stage based on TNM compared to the advanced stage. FAPI-SUVmax in 49% of all lesions were SUVmax ≥ 6, and 13% were SUVmax ≥ 10. In patient-based analyses, seven patients (39%) had at least one lesion with FAPI-SUVmax ≥ 10; 12 patients (67%) had at least one lesion with FAPI-SUVmax ≥ 6. This study showed the potential utility of [68 Ga]Ga-FAPI-04 PET/CT showing promising results in RCC. We have presumed that FAPI-PET/CT may be performed for complementary imaging modality providing prognosis and possibility of theranostic application in selected patients.
Identifiants
pubmed: 37803246
doi: 10.1007/s00259-023-06461-4
pii: 10.1007/s00259-023-06461-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 Update. Eur Urol. 2022;82:529–42. https://doi.org/10.1016/j.eururo.2022.08.019 .
doi: 10.1016/j.eururo.2022.08.019
pubmed: 36100483
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 world health organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2022;82:458–68. https://doi.org/10.1016/j.eururo.2022.06.016 .
doi: 10.1016/j.eururo.2022.06.016
pubmed: 35853783
Sohlberg EM, Metzner TJ, Leppert JT. The harms of overdiagnosis and overtreatment in patients with small renal masses: a mini-review. Eur Urol Focus. 2019;5:943–5. https://doi.org/10.1016/j.euf.2019.03.006 .
doi: 10.1016/j.euf.2019.03.006
pubmed: 30905599
Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European Association of Urology Guidelines on renal cell carcinoma: The 2022 Update. Eur Urol. 2022;82:399–410. https://doi.org/10.1016/j.eururo.2022.03.006 .
doi: 10.1016/j.eururo.2022.03.006
pubmed: 35346519
Oflas M, Ozluk Y, Sanli O, Ozkan ZG, Kuyumcu S. 68Ga-PSMA Uptake patterns of clear cell renal carcinoma across different histopathological subtypes. Clin Nucl Med. 2022;47:e45–6. https://doi.org/10.1097/rlu.0000000000003814 .
doi: 10.1097/rlu.0000000000003814
pubmed: 34284482
Has Simsek D, Civan C, Erdem S, Sanli Y. Complementary role of 68Ga-prostate-specific membrane antigen and 18F-FDG PET/CT for evaluation of metastases and treatment response in renal cell carcinoma. Clin Nucl Med. 2021;46:579–81. https://doi.org/10.1097/rlu.0000000000003590 .
doi: 10.1097/rlu.0000000000003590
pubmed: 33782292
Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, et al. Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:1931–9. https://doi.org/10.1007/s00259-019-04358-9 .
doi: 10.1007/s00259-019-04358-9
pubmed: 31172212
pmcid: 6647180
Parihar AS, Mhlanga J, Ronstrom C, Schmidt LR, Figenshau RS, Dehdashti F, et al. Diagnostic accuracy of (99m)Tc-Sestamibi SPECT/CT for characterization of solid renal masses. J Nucl Med. 2023;64:90–5. https://doi.org/10.2967/jnumed.122.264329 .
doi: 10.2967/jnumed.122.264329
pubmed: 35772963
Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38:156–63. https://doi.org/10.1097/mnm.0000000000000618 .
doi: 10.1097/mnm.0000000000000618
pubmed: 27824726
Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med. 2015;40:936–40. https://doi.org/10.1097/rlu.0000000000000875 .
doi: 10.1097/rlu.0000000000000875
pubmed: 26164183
pmcid: 4890815
Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol. 2016;6:201. https://doi.org/10.3389/fonc.2016.00201 .
doi: 10.3389/fonc.2016.00201
pubmed: 27656421
pmcid: 5012103
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5. https://doi.org/10.2967/jnumed.119.227967 .
doi: 10.2967/jnumed.119.227967
pubmed: 30954939
pmcid: 6581228
Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management. Front Oncol. 2021;11: 758958. https://doi.org/10.3389/fonc.2021.758958 .
doi: 10.3389/fonc.2021.758958
pubmed: 34858834
pmcid: 8632139
Kuyumcu S, Kovan B, Sanli Y, Buyukkaya F, Has Simsek D, Özkan ZG, et al. Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04. Clin Nucl Med. 2021;46:641–6. https://doi.org/10.1097/rlu.0000000000003667 .
doi: 10.1097/rlu.0000000000003667
pubmed: 33883494
Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92. https://doi.org/10.2967/jnumed.118.215913 .
doi: 10.2967/jnumed.118.215913
pubmed: 30072500
pmcid: 6424229
Solano-Iturri JD, Errarte P, Etxezarraga MC, Echevarria E, Angulo J, López JI, et al. Altered tissue and plasma levels of fibroblast activation protein-α (FAP) in renal tumours. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12113393 .
Yang J, Dong A, Zuo C. 68Ga-FAPI-04 PET/CT in solitary choroid plexus metastasis from renal cell carcinoma. Clin Nucl Med. 2022;47:885–7. https://doi.org/10.1097/rlu.0000000000004207 .
doi: 10.1097/rlu.0000000000004207
pubmed: 36067086
Civan C, Isik EG, Karadogan S, Sanli Y, Kuyumcu S. 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT in metastatic papillary renal cell cancer. Clin Nucl Med. 2023. https://doi.org/10.1097/rlu.0000000000004587 .
doi: 10.1097/rlu.0000000000004587
pubmed: 37220240
Xie F, Fu L, Zhou W. Superiority of 68Ga-FAPI-04 in delineation of soft tissue and liver metastases in chromophobe renal cell carcinoma for restaging. Clin Nucl Med. 2022;47:e758–9. https://doi.org/10.1097/rlu.0000000000004374 .
doi: 10.1097/rlu.0000000000004374
pubmed: 36342807
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x .
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Zhong X, Guo J, Han X, Wu W, Yang R, Zhang J, et al. Synthesis and preclinical evaluation of a novel FAPI-04 dimer for cancer theranostics. Mol Pharm. 2023;20:2402–14. https://doi.org/10.1021/acs.molpharmaceut.2c00965 .
doi: 10.1021/acs.molpharmaceut.2c00965
pubmed: 37015025
Liu X, Liu H, Gao C, Zeng W. Comparison of (68)Ga-FAPI and (18)F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: a systematic review and meta-analysis. Front Oncol. 2023;13:1093861. https://doi.org/10.3389/fonc.2023.1093861 .
doi: 10.3389/fonc.2023.1093861
pubmed: 36874127
pmcid: 9982086
Dong A, Yang B, Bai Y, Zuo C. 68 Ga-FAPI-04 PET/CT in a small sarcomatoid renal cell carcinoma with widespread metastases. Clin Nucl Med. 2023;48:457–9. https://doi.org/10.1097/rlu.0000000000004607 .
doi: 10.1097/rlu.0000000000004607
pubmed: 36800242
Çermik TF, Ergül N, Yılmaz B, Mercanoğlu G. Tumor imaging with 68Ga-DOTA-FAPI-04 PET/CT: comparison with 18F-FDG PET/CT in 22 different cancer types. Clin Nucl Med. 2022;47:e333–9. https://doi.org/10.1097/rlu.0000000000004073 .
doi: 10.1097/rlu.0000000000004073
pubmed: 35085165
Zheng S, Lin R, Chen S, Zheng J, Lin Z, Zhang Y, et al. Characterization of the benign lesions with increased (68)Ga-FAPI-04 uptake in PET/CT. Ann Nucl Med. 2021;35:1312–20. https://doi.org/10.1007/s12149-021-01673-w .
doi: 10.1007/s12149-021-01673-w
pubmed: 34424505
Civan C, Isik EG, Has Simsek D, Buyukkaya F, Kuyumcu S. Utility of 68 Ga-FAPI-04 PET/CT in adenoid cystic carcinoma compared with 18 F-FDG PET/CT : two case reports. Clin Nucl Med. 2023;48:e350–2. https://doi.org/10.1097/rlu.0000000000004687 .
doi: 10.1097/rlu.0000000000004687
pubmed: 37167284
Karivedu V, Jain AL, Eluvathingal TJ, Sidana A. Role of positron emission tomography imaging in metabolically active renal cell carcinoma. Curr Urol Rep. 2019;20:56. https://doi.org/10.1007/s11934-019-0932-2 .
doi: 10.1007/s11934-019-0932-2
pubmed: 31468240
Nakamoto Y, Ishimori T, Shimizu Y, Sano K, Togashi K. Clinical utility of (68)Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:1524–30. https://doi.org/10.1007/s00259-019-04298-4 .
doi: 10.1007/s00259-019-04298-4
pubmed: 30847538
Evangelista L, Zattoni F, Alongi P. (68)Ga-dotatoc vs. (18)F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients. Ann Transl Med. 2019;7:S150. https://doi.org/10.21037/atm.2019.06.28 .
doi: 10.21037/atm.2019.06.28
pubmed: 31576357
pmcid: 6685849
Tariq A, Kwok M, Pearce A, Rhee H, Kyle S, Marsh P, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: a multi-institutional case series with intra-individual comparison. Urol Oncol. 2022;40:66.e1-.e9. https://doi.org/10.1016/j.urolonc.2021.11.006 .
doi: 10.1016/j.urolonc.2021.11.006
pubmed: 34895817
Udovicich C, Callahan J, Bressel M, Ong WL, Perera M, Tran B, et al. Impact of prostate-specific membrane antigen positron emission tomography/computed tomography in the management of oligometastatic renal cell carcinoma. Eur Urol Open Sci. 2022;44:60–8. https://doi.org/10.1016/j.euros.2022.08.001 .
doi: 10.1016/j.euros.2022.08.001
pubmed: 36185587
pmcid: 9520507
Bentestuen M, Al-Obaydi N, Zacho HD. FAPI-avid nonmalignant PET/CT findings: an expedited systematic review. Semin Nucl Med. 2023. https://doi.org/10.1053/j.semnuclmed.2023.02.001 .
doi: 10.1053/j.semnuclmed.2023.02.001
pubmed: 36813670
Dong A, Yang Q, Hua M, Cheng C, Zuo C. Lipid-poor renal angiomyolipoma mimicking renal cell carcinoma on 68 Ga-FAPI-04 PET/CT. Clin Nucl Med. 2022;47:991–3. https://doi.org/10.1097/rlu.0000000000004297 .
doi: 10.1097/rlu.0000000000004297
pubmed: 35619202
Qin C, Gai Y, Liu Q, Shao F, Lan X. Elevated 68Ga-FAPI accumulation in a recurrent angiomyolipoma. Clin Nucl Med. 2020;45:1034–5. https://doi.org/10.1097/rlu.0000000000003345 .
doi: 10.1097/rlu.0000000000003345
pubmed: 33086278
Dell’Aprovitola N, Guarino S, Del Vecchio W, Camera L, Chiancone F, Imbimbo C, et al. Xanthogranulomatous pyelonephritis mimicking a renal cell carcinoma: a unique and challenging case. Acta Radiol Short Rep. 2014;3:2047981613513763. https://doi.org/10.1177/2047981613513763 .
doi: 10.1177/2047981613513763
pubmed: 24778797
pmcid: 4001428
Joshi P, Lele V, Shah H. Fluorodeoxyglucose positron emission tomography-computed tomography findings in a case of xanthogranulomatous pyelonephritis. Indian J Nucl Med. 2013;28:49–50. https://doi.org/10.4103/0972-3919.116809 .
doi: 10.4103/0972-3919.116809
pubmed: 24019680
pmcid: 3764696
Fendler WP, Pabst KM, Kessler L, Fragoso Costa P, Ferdinandus J, Weber M, et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin Cancer Res. 2022;28:4346–53. https://doi.org/10.1158/1078-0432.Ccr-22-1432 .
doi: 10.1158/1078-0432.Ccr-22-1432
pubmed: 35833949
pmcid: 9527500
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, et al. Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities. J Nucl Med. 2023;64:711–6. https://doi.org/10.2967/jnumed.122.264689 .
doi: 10.2967/jnumed.122.264689
pubmed: 36581374